$ESLAW
Estrella Immunopharma, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances) · Emeryville, CA
ESLAW chart
What traders are saying about $ESLAW
Latest postsEstrella Immunopharma, Inc. news
- What Lifted Estrella Immunopharma (NASDAQ:ESLA) 8.63% as It Regained USD 1.00 With No Release?
kalkine.ca ·
- Estrella Immunopharma Appoints Cynthia Pussinen CEO and Board Chair
citybiz ·
- Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Yahoo Finance ·
- Estrella Immunopharma, Inc. Estimates – NASDAQ:ESLAW
TradingView ·
- Why Is Estrella Immunopharma (NASDAQ:ESLA) Penny Stock Climbing 11% as Its Lymphoma Trial Adds Sites?
kalkine.ca ·
- What Is Powering the Rally in Karyopharm Therapeutics, Estrella Immunopharma, CytoSorbents, MoonLake Immunotherapeutics, FibroBiologics, Exicure, Biohaven and Profusa Stocks Today, and What Should Investors Know About the Catalysts?
kalkine.ca ·
- Estrella Immunopharma Shares Rise 17.91% After Hours - Estrella Immunopharma (NASDAQ:ESLA)
Benzinga ·
- Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Yahoo Finance ·
- Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
Yahoo Finance ·
- Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
- Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Yahoo Finance ·
Estrella Immunopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996,104 |
| Diluted EPS | $-0.35 | $-0.27 | $-36.35 | – |
| Total assets (year end) | $3.2M | $3.1M | $9.4M | $9.7M |
| Cash and equivalents (year end) | $1.4M | $916,916 | $9.0M | $40,802 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Estrella Immunopharma, Inc.
- Ticker
- ESLAW (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp.
Frequently asked questions
What exchange is Estrella Immunopharma, Inc. listed on?
Estrella Immunopharma, Inc. trades on the Nasdaq under the ticker symbol ESLAW.
What industry is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)".
Where is Estrella Immunopharma, Inc. headquartered?
Estrella Immunopharma, Inc.'s business address on file with the SEC is in Emeryville, CA.
When does Estrella Immunopharma, Inc.'s fiscal year end?
Estrella Immunopharma, Inc.'s fiscal year ends on December 31.